Aripiprazole for Hair-Pulling and Skin-Picking Disorders
This study is testing aripiprazole, an atypical antipsychotic medication, against a placebo (a drug with no medicine) for adults with trichotillomania (hair-pulling disorder) or dermatillomania (skin-picking disorder). The goal is to see if aripiprazole is effective and safe for these conditions, which currently lack clear treatments. You would be randomly assigned to receive either aripiprazole or placebo. The study will measure changes in symptom severity using the NIMH Symptom Severity Scale over six weeks to determine if the treatment is successful. We are looking for 100 participants aged 18 and older who have a current diagnosis of one of these disorders and can understand and sign a consent form.
- Study design
- This is an interventional study with 100 planned participants, randomized 1:1 to receive either aripiprazole or placebo. It is a blinded study, meaning neither you nor your doctors will know which treatment you are receiving.
- What's involved
- The study lasts 6 weeks. If assigned to aripiprazole, you would take 5mg daily for two weeks, then 10mg daily for three weeks. Efficacy and safety measures will be performed at each visit.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary efficacy endpoints are measured at week 6.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Aripiprazole in Body Focused Repetitive Behaviors
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jon E Grant, MD, JD, MPH · PRINCIPAL_INVESTIGATOR · University of Chicago
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- NIMH Symptom Severity Scale (for TTM or Skin Picking)The primary efficacy end points will be the change in these measures from baseline to week 6.
The primary efficacy measure will be the change in hair pulling or skin picking frequency and urges to pull hair or pick skin for the past week as indicated by change in total score. The entire study lasts 6 weeks. Every two weeks subjects will take the NIMH-TSS. The change in scores from baseline to after 6 weeks will be assessed. The scale itself assesses severity of trichotillomania symptoms. The NIMH-TSS score ranges from 0 to 20, with 0 being no symptoms and 20 being the most severe.